Aphios
Aphios Corporation is an innovative biotechnology company dedicated to advancing health through sustainable science. They develop enabling technology platforms to improve drug discovery, manufacturing, nanotechnology drug delivery, and pathogen safety. The company focuses on therapeutics for cancer, infectious diseases such as HIV, CNS disorders including Alzheimer’s disease, opioid addiction, and more, with a mission inspired by nature and enabled by science. They actively engage in community involvement, internships, and support for various charitable causes.
Industries
Nr. of Employees
small (1-50)
Aphios
Patents
Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
US-10828276-B2
View Details
Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
US-10828276-B2
View DetailsProducts
Enhanced ginger formulation for chemotherapy-associated nausea and vomiting (adjunctive therapy)
An enhanced natural-product formulation developed for chemotherapy-induced nausea and vomiting (CINV) with clinical evaluation in randomized multicenter trials.
PKC-activator therapeutic for neurodegenerative disease (intravenous and oral reformulations)
A small-molecule PKC modulator developed for amelioration of Alzheimer’s disease pathophysiology with intravenous clinical evaluation and reformulation efforts for oral administration using nanoparticle-based delivery methods.
Combination HIV-latency nanotherapeutic (co-encapsulated latency reversal agents)
A nanoparticle formulation co-encapsulating a protein kinase C modulator and a histone deacetylase inhibitor designed to reactivate latent HIV reservoirs for clearance.
Sustained-release cannabidiol (CBD) nanoparticles for opioid relapse prevention
Biodegradable polymer nanoparticle formulation of cannabidiol designed for sustained release to reduce opioid cravings and withdrawal-related behaviors (NIH SBIR-funded development).
Enhanced ginger formulation for chemotherapy-associated nausea and vomiting (adjunctive therapy)
An enhanced natural-product formulation developed for chemotherapy-induced nausea and vomiting (CINV) with clinical evaluation in randomized multicenter trials.
PKC-activator therapeutic for neurodegenerative disease (intravenous and oral reformulations)
A small-molecule PKC modulator developed for amelioration of Alzheimer’s disease pathophysiology with intravenous clinical evaluation and reformulation efforts for oral administration using nanoparticle-based delivery methods.
Combination HIV-latency nanotherapeutic (co-encapsulated latency reversal agents)
A nanoparticle formulation co-encapsulating a protein kinase C modulator and a histone deacetylase inhibitor designed to reactivate latent HIV reservoirs for clearance.
Sustained-release cannabidiol (CBD) nanoparticles for opioid relapse prevention
Biodegradable polymer nanoparticle formulation of cannabidiol designed for sustained release to reduce opioid cravings and withdrawal-related behaviors (NIH SBIR-funded development).
Services
Small-scale contract manufacture and sterile formulation of APIs and clinical supplies for early-stage trials and quality-of-life medicines.
Synthesis and distribution of rare, complex natural-product research chemicals and APIs for use as standards or research materials.
Out-licensing and collaborative partnerships around enabling technology platforms for drug delivery, manufacturing acceleration and pathogen safety.
Provision of incubator laboratory space, cGMP-compliant facilities and access to higher-containment laboratory capacity for startups and external partners.
Small-scale contract manufacture and sterile formulation of APIs and clinical supplies for early-stage trials and quality-of-life medicines.
Synthesis and distribution of rare, complex natural-product research chemicals and APIs for use as standards or research materials.
Out-licensing and collaborative partnerships around enabling technology platforms for drug delivery, manufacturing acceleration and pathogen safety.
Provision of incubator laboratory space, cGMP-compliant facilities and access to higher-containment laboratory capacity for startups and external partners.
Expertise Areas
- Nanotechnology drug delivery
- Preclinical animal models and efficacy testing
- Clinical trial design and execution (Phase II–III)
- Formulation development and CMC for oral and intravenous routes
Key Technologies
- Phospholipid-based nanoparticle systems
- Biodegradable polymer nanoparticle formulations
- Surface modification for long-circulating nanoparticles (e.g., PEGylation)
- Co-encapsulation (multi-drug nanoparticle delivery)
News & Updates
Aphios participated in the BIO Digital conference held online from June 8-12, 2020.
Aphios announced it received a U.S. patent allowance for a room temperature-stable, single-shot mRNA COVID-19 vaccine.
Aphios was awarded an NIH SBIR grant to develop anti-CCR5 nanoparticles for Alzheimer’s disease.
Aphios participated in the BIO Digital conference held online from June 8-12, 2020.
Aphios announced it received a U.S. patent allowance for a room temperature-stable, single-shot mRNA COVID-19 vaccine.
Aphios was awarded an NIH SBIR grant to develop anti-CCR5 nanoparticles for Alzheimer’s disease.